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a  b  s  t  r  a  c  t
INTRODUCTION:  Differentiated  thyroid  carcinomas  (DTC)  have  good  prognoses  after  complete  resection.
Nevertheless,  when  DTC  is associated  with  an  aerodigestive  invasion,  curative  surgery  is  difficult  to
perform.  However,  there  is  no  established  neoadjuvant  therapy  for  advanced  DTC.
PRESENTATION  OF  CASE:  A  73-year-old  man  with  thyroid  papillary  carcinoma  was  referred  to our hospital.
A computed  tomography  examination  revealed  a tumor  in  the  upper  right  lobe  of  the  thyroid,  and  multiple
bilateral  enlarged  lymph  nodes  in  the  neck,  involving  the  surrounding  structures.  The  enlarged  lymph
node  at  the  right  upper  neck  was  suspected  to have  invaded  the  right  internal  jugular  vein,  and  the  left
paratracheal  lymph  node  was  suspected  to have  invaded  the  cervical  esophagus  and  trachea.  The  tumor
was considered  resectable;  however,  surgery  would  have  been  highly  invasive.  Therefore,  we initiated
neoadjuvant  therapy  with  lenvatinib.  After  administration  of lenvatinib,  the  tumor  decreased  in size by
84.3%  and  the  cervical  lymph  nodes  by  56.0%.  The  patient  underwent  a total  thyroidectomy,  modified
neck  dissection,  a resection  of  the  muscular  layer  of  the  esophagus,  and  a tracheal  sleeve  resection  and
reconstruction.
DISCUSSION:  The  SELECT  trial  demonstrated  that  lenvatinib  had  high  response  rate  with  short  response
time,  in  patients  with  radioiodine-refractory  DTC.  The  results  suggested  that  lenvatinib  could  be  effective
as  neoadjuvant  therapy.
CONCLUSION:  For  an  advanced  DTC  that requires  removal  through  invasive  surgery,  preoperative  lenva-
tinib treatment  might  be one  of  the  options  for  a less  invasive  surgery.
© 2017  The  Authors.  Published  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Generally, differentiated thyroid carcinomas (DTC) have good
rognoses after complete resection; most patients with DTC are
reated with a primary surgery. However, we sometimes encounter
atients with locally advanced DTC, which has invaded surrounding
tructures. Direct invasion of the larynx, trachea, pharynx, esopha-
us, recurrent laryngeal nerve, strap muscles, and/or carotid artery
ccurs in 7–16% of patients with thyroid cancer [1]. The treatment
trategy is difficult in such cases because it is difficult to resect com-
letely, a locally advanced DTC without invasion of these critical
tructures.Guidelines of the American Thyroid Association [2] recommend
hat the surgical removal of an aerodigestive invasive DTC should
e performed in combination with radioactive iodine (RAI) ther-
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apy, and/or external beam radiotherapy. However, there are few
institutions permitted to perform RAI therapy in Japan because of
severe restrictions in the handling of RAI. Therefore, a patient in
need of RAI will have to wait for an unreasonable length of time to
have access to the therapy. Moreover, a neoadjuvant external beam
radiation therapy can lead to fibrosis, which can make surgery even
more complicated for the surgeon.
Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor
(TKI) of the VEGFRs 1–3, FGFRs 1–4, PDGFR , RET, and KIT signal-
ing networks [3,4]. Previously reported results of the SELECT trial
demonstrated that lenvatinib significantly prolonged progression-
free survival (PFS) in patients with RAI-refractory DTC, compared
with those on placebo [5]. Based on this and several other
reports [6,7] about the role of chemotherapy in DTC, unresectable
locally advanced DTC that invades critical structures can become
resectable after neoadjuvant chemotherapy with lenvatinib. How-
ever, there has been no report on neoadjuvant chemotherapy in
advanced DTC with TKI.We report on a locally advanced papillary thyroid carcinoma,
which was difficult to resect because of invasion of the jugular
vein, trachea, and esophagus, in a 73-year-old man  who  under-
went surgery after preoperative chemotherapy with lenvatinib.
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. A computed tomography examination revealed a mass, measuring 18 × 17 mm in the upper right lobe of thyroid (A) and swollen lymph nodes in neck: the lymph
node  at the right upper neck suspected invasion of right internal jugular vein (B), the left paratracheal lymph node suspected invasion of cervical esophagus and trachea (C).
Bronchoscope examination revealed tumor invasion in tracheal lumen (D).
Fig. 2. A computed tomography examination showed tumor reduction: (A) lymph node at the right neck decreased in size by 84.3%, (B) left parabronchial lymph node
decreased in size by 56.0%, and (C) thyroid tumor decreased in size by 5.9%. (i) before treatment, (ii) after treatment.
 –  OPEN  ACCESS
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his manuscript has been reported in accordance with the SCARE
riteria [8].
. Case presentation
A 73-year-old man  presented to a hospital with a right neck
ass and hoarseness. He was diagnosed with a thyroid papillary
arcinoma, and was referred to our hospital for further treat-
ent. Upon physical examination, we found a large hard immobile
ass in the right neck. Standard laboratory test results on serum
nd urine showed no significant findings. Thyroid function test
howed low thyroid-stimulating hormone (TSH): 0.03 U/mL (ref-
rence range: 0.74–4.12), normal free thyroxine (fT4): 1.18 ng/dL
reference range: 0.70–1.25), and high free triiodothyronine (fT3):
.6 pg/mL (reference range: 2.5–3.5). Thyroglobulin level was  ele-
ated to 478 ng/mL (reference range ≤33.7). Tumor markers such
s carcinoembryonic antigen and squamous cell carcinoma anti-
en were within the reference limits. Computed tomography (CT)
evealed a mass, measuring 18 × 17 mm in the upper right lobe of
he thyroid, and multiple bilateral lymph nodes in the neck, involv-
ng surrounding structures. The enlarged lymph node, measuring
3 × 27 mm  at the right upper neck was suspected to have invaded
he right internal jugular vein. The left paratracheal lymph node,
easuring 30 × 25 mm was suspected to have invaded the cervi-
al esophagus and trachea (Fig. 1A–C). These lymph nodes were
ot biopsied; however, they were considered lymph node metas-
ases by CT findings. There was no apparent distant metastasis.
 bronchoscopy revealed a tumor invasion in the tracheal lumen
Fig. 1D). An esophagogastroduodenoscopy revealed the absence of
 tumor invasion in the inner lumen of the esophagus. However, the
rocedure to dissect the tumor and concurrently preserve the cer-
ical esophagus was considered difficult, since according to the CT,
he tumor and the cervical esophagus had no defined boundaries.
 diagnosis of clinical thyroid papillary carcinoma (T4a N1b M0,
tage IVA) was made. We  judged the tumor as resectable; however,
e were concerned that a resection and reconstruction of a wide
tretch of the esophagus and trachea would be highly invasive. We
xplained the condition of the disease and our planned procedure;
owever, the patient refused immediate surgery owing to the high
nvasiveness of the procedure. On the other hand, the patient would
ave had to wait for nearly one year in our hospital, to have access
o RAI therapy. Due to the above reasons, he began chemother-
py treatment with lenvatinib. Since the tumor was suspected
o have invaded the trachea, the muscular layer of the esopha-
us, and the right internal jugular vein, lenvatinib administration
as started at 14 mg  per body weight, considering, the possibil-
ty for aerodigestive fistula and tumor bleeding. Although grade
 proteinuria and hypertension were observed, these were con-
rolled with antihypertensive agents, dose reduction of lenvatinib,
nd the withdrawal of chemotherapy. A follow-up CT examination
as performed on the patient to assess the therapeutic effect of
envatinib. After administration of lenvatinib (total dose, 966 mg
or 22 weeks; including total of 4 weeks of withdrawal during the
dministration period), the tumor decreased in size by 84.3%, the
ervical lymph nodes by 56.0% (Fig. 2A, B), and the thyroid papil-
ary carcinoma by 5.9% (Fig. 2C). The metastatic lymph node and
ervical esophagus showed well-defined boundaries. Thyroglobu-
in level decreased to 101 ng/mL. Bronchoscopy showed a residual
umor in the tracheal lumen; however, the tumor was reduced
Fig. 3). Based on these findings, we believed that surgery could be
ess invasive, and thus, the cervical esophagus could be preserved.
ventually, the patient consented to surgery, which he underwent
fter 17 days from the last administration of lenvatinib. The surgi-
al procedure consisted total thyroidectomy, a modified right neck
issection, a resection of the muscular layer of the esophagus, andFig. 3. After lenvatinib therapy, a bronchoscopy showed a residual tumor in the
tracheal lumen, but tumor was reduced.
a tracheal sleeve resection and reconstruction. A cavity was located
in the resected thyroid tumor; this might have been the result of
tumor necrosis, caused by the efficacy of the lenvatinib therapy.
He was discharged 14 days after the surgery without postoperative
complications, or adjuvant chemotherapy. No macroscopic residual
tumor was found in the surrounding tissues during the operation,
but histologically, a microscopic invasion was found at the edge of
the resected bronchial wall. An appointment was booked after 11
months for RAI therapy. There has been no distant metastasis for
10 months post-surgery.
3. Discussion
Although there are some reports of preoperative therapy for
DTC, there is no established neoadjuvant therapy for advanced DTC
because it is not common to have a difficult complete resection of
a DTC.
Shingu et al. reported a case of resection of locally advanced
DTC after response to preoperative RAI therapy [9]. In their case,
unresectable DTC became resectable due to RAI therapy; therefore,
preoperative therapy for advanced DTC is considered very effective.
There have been some reports of neoadjuvant chemother-
apy for DTC [6,7]. Basic et al. reported findings of patients with
T3/T4 papillary thyroid carcinoma who  were treated with neoadju-
vant chemotherapy of vinblastine, Adriamycin, or other regimens;
tumor size decreased by >50% in 44.8% of the patients. They also
reported that neoadjuvant chemotherapy in patients with locally
advanced follicular or Hürthle cell thyroid carcinoma reduced
tumor size by >50% in 45% of those patients. Based on the results
of these studies, we hypothesized that neoadjuvant chemotherapy
might be effective in DTC.
Generally, targeted therapy is considered more effective and
less toxic than conventional cytotoxic chemotherapy. However,
no study has been conducted to assess the effect of neoadjuvant
chemotherapy on DTC with TKI. In the SELECT trial, lenvatinib sig-
nificantly prolonged median progression-free survival (PFS; the
primary endpoint) in patients with progressive RAI-refractory DTC,
compared with those on placebo. In one study, the response rate of
lenvatinib was  found to be 64.8%, while the median response time
was 2.0 months [5]. This short response time and high response
 –  O
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ate suggests that lenvatinib is a good candidate for neoadjuvant
hemotherapy in DTC.
It is well known that the inhibition of blood vessel formation via
ntiangiogenic agents can impair wound healing. Lenvatinib has a
edian half-life of 35 h; 7 days of withdrawal was  required before
 major surgery in the SELECT trial. In our case, lenvatinib was  dis-
ontinued 17 days before surgery and there was no perioperative
omplication. Perioperative VEGF-targeted therapies can be safe
hen an appropriate interval period is allowed before surgery.
Fistula formation, although a rare side effect of antiangiogenic
KI, can be life threatening. In our case, there were concerns about
 possible formation of an aerodigestive fistula, due to the pres-
nce of the tumor adjacent the esophagus and bronchus, as well as
leeding due to the presence of the tumor adjacent the right inter-
al jugular vein. Therefore, the patient was started on lenvatinib
4 mg/day and followed up carefully with frequent CT examina-
ions. After administration of lenvatinib, the tumor in the right lobe
f thyroid did not show any remarkable efficacy compared to the
etastatic lymph nodes. The reason may  have been that the effect
f lenvatinib on the thyroid tumor resulted in the formation of a
avity due to internal necrosis of the tumor. We  also thought that
 progression in the formation of such a cavity might finally lead to
he formation of a fistula. Particular caution is needed when lenva-
inib is being administered to a patient whose tumor metastasizes
nto vital structures such as the esophagus, the trachea, and the
ajor blood vessels.
. Conclusion
In summary, we reported a case of a locally advanced papillary
hyroid carcinoma that was resected after preoperative lenvatinib
reatment without perioperative complications. For an advanced
TC that requires removal through invasive surgery, preoperative
envatinib treatment might be one of the options for a less inva-
ive surgery. This case was not placed on a study protocol because
f necessity of immediate treatment, However, future studies will
eed to elucidate the possibilities for neoadjuvant chemotherapy
f TKI in advanced DTC.
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